EPRX logo

Eupraxia Pharmaceuticals Inc.

EPRX
Healthcare|Biotechnology|CA
$6.89
+0.29 (+4.39%)
DCF Value
$1.44
Tangible Book / Share
$1.95
Cash / Share
$2.02
Financing Filings (last 12 months)
2
Shelf registrations / offering prospectuses — latest Aug 19, 2026 (F-10/A). Possible dilution.

Upcoming Data Readouts (1)

Dec 2026
Est. completion
P1P2Eosinophilic Esophagitis
A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).
NCT05608681n=117

Recent Press Releases

Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day
Oct 22, 2026 · GlobeNewsWire
Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
Oct 15, 2026 · GlobeNewsWire
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
Oct 9, 2026 · GlobeNewsWire
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
Sep 30, 2026 · GlobeNewsWire
Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences
Sep 8, 2026 · GlobeNewsWire
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
Aug 13, 2026 · GlobeNewsWire
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
Aug 11, 2026 · GlobeNewsWire

SEC Filings (76)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 22, 20266-KForeign issuer reportDocumentIndex
Oct 15, 20266-KForeign issuer reportDocumentIndex
Oct 9, 20266-KForeign issuer reportDocumentIndex
Sep 30, 20266-KForeign issuer reportDocumentIndex
Sep 8, 20266-KForeign issuer reportDocumentIndex
Sep 2, 2026SUPPLDocumentIndex
Aug 24, 2026EFFECTDocumentIndex
Aug 19, 2026F-10/AIPO / offering registrationDocumentIndex
Aug 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 13, 20266-KForeign issuer reportDocumentIndex
Aug 11, 20266-KForeign issuer reportDocumentIndex
Aug 6, 2026F-XDocumentIndex
Aug 6, 2026F-10IPO / offering registrationDocumentIndex
Jul 15, 20266-KForeign issuer reportDocumentIndex
Jul 13, 20266-KForeign issuer reportDocumentIndex
Jul 7, 20266-KForeign issuer reportDocumentIndex
Jun 22, 20266-KForeign issuer reportDocumentIndex
May 29, 20266-KForeign issuer reportDocumentIndex
May 29, 20266-KForeign issuer reportDocumentIndex
May 28, 20266-KForeign issuer reportDocumentIndex
May 12, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 12, 20266-KForeign issuer reportDocumentIndex
May 6, 20266-KForeign issuer reportDocumentIndex
May 5, 20266-KForeign issuer reportDocumentIndex
May 1, 20266-KForeign issuer reportDocumentIndex
Apr 22, 20266-KForeign issuer reportDocumentIndex
Apr 21, 20266-KForeign issuer reportDocumentIndex
Apr 15, 20266-KForeign issuer reportDocumentIndex
Apr 15, 20266-KForeign issuer reportDocumentIndex
Mar 17, 20266-KForeign issuer reportDocumentIndex
Mar 16, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
Mar 13, 202640-FAnnual report (foreign)DocumentIndex
Mar 6, 20266-KForeign issuer reportDocumentIndex
Feb 20, 20266-KForeign issuer reportDocumentIndex
Feb 20, 2026SUPPLDocumentIndex
Feb 20, 20266-KForeign issuer reportDocumentIndex
Feb 19, 20266-KForeign issuer reportDocumentIndex
Feb 18, 2026SUPPLDocumentIndex
Feb 18, 20266-KForeign issuer reportDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex